Advanced search
Publication Cover
Future Lipidology Volume 1, 2006 - Issue 4
Journal homepage
94
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Future approaches to reducing low-density lipoprotein cholesterol

Anthony WierzbickiSt.Thomas’ Hospital, Consultant in Chemical Pathology, Lambeth Palace Road, London, SE1 7EH, UK, Tel.: +44 207 188 1256 Fax.: + 44 207 928 4226, E-mail: [email protected]Correspondence[email protected]
Pages 463-476 | Published online: 18 Jan 2017

  • Yusuf S, Hawken S, Ounpuu S et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364(9438), 937–952 (2004).
  • Epidemiology of world coronary artery disease.
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001).
  • Definition of low-density lipoprotein cholesterol (LDL-C) targets in the USA.
  • British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association: JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 91 (Suppl. V), V1–V52 (2005).
  • Latest British guidelines for management of cardiovascular disease.
  • Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
  • Meta-analysis of effects of LDL-C reduction in the statin trials.
  • Smith SC Jr, Allen J, Blair SN et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363–2372 (2006).
  • Latest update of USA guidelines concentration on LDL-C and non-high-density lipoprotein cholesterol (HDL-C) targets.
  • Cannon CP, Braunwald E, McCabe CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495–1504 (2004).
  • Low- versus high-dose statin therapy for acute coronary syndromes.
  • de Lemos JA, Blazing MA, Wiviott SD et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11), 1307–1316 (2004).
  • Moderate- versus high-dose statin therapy for acute coronary syndromes.
  • Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9), 1071–1080 (2004).
  • LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425–1435 (2005).
  • Low- versus high-dose statin therapy in chronic coronary heart disease (CHD).
  • Pedersen TR, Faergeman O, Kastelein JJ et al.: High-dose atorvastatin vs usualdose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294(19), 2437–2445 (2005).
  • Low versus high dose statin therapy in chronic CHD.
  • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7–22 (2002).
  • Athyros VG, Papageorgiou AA, Mercouris BR et al.: Treatment with atorvastatin to the National Cholesterol Educational Program Goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr. Med. Res. Opin. 18(4), 220–228 (2002).
  • Aggressive treatment-to-target with statin therapy in CHD.
  • Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E: Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J. Am. Coll. Cardiol. 46(8), 1411–1416 (2005).
  • Nissen SE, Nicholls SJ, Sipahi I et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID Trial. JAMA 13 1556–1565 (2006).
  • Garcia PJ. Pleiotropic effects of statins: moving beyond cholesterol control. Curr. Atheroscler. Rep. 7(1), 34–39 (2005).
  • Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol. Ther. 99(1), 95–112 (2003).
  • Reviews the clinical pharmacology and pleiotropic effects of statins.
  • Bucher HC, Griffith LE, Guyatt GH: Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler. Thromb. Vasc. Biol. 19(2), 187–195 (1999).
  • Ray KK, Cannon CP, Cairns R et al.: Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 46(8), 1417–1424 (2005).
  • Ridker PM, Rifai N, Clearfield M et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344(26), 1959–1965 (2001).
  • Gotto AM Jr, Whitney E, Stein EA et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101(5), 477–484 (2000).
  • Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358(9298), 2026–2033 (2001).
  • Silva MA, Swanson AC, Gandhi PJ, Tataronis GR: Statin-related adverse events: a metaanalysis. Clin. Ther. 28(1), 26–35 (2006).
  • Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA: Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am. J. Med. 118(6), 618–624 (2005).
  • Wierzbicki AS, Lumb PJ, Semra YK, Crook MA: Effect of atorvastatin on plasma fibrinogen. Lancet 351(9102), 569–570 (1998).
  • Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA: Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 92(7), 387–394 (1999).
  • Wierzbicki AS, Lumb PJ, Chik G: Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia. Int. J. Clin. Pract. 55(10), 673–675 (2001).
  • Claudel T, Staels B, Kuipers F: The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25(10), 2020–2030 (2005).
  • Bruckert E, Hayem G, Dejager S, Yau C, Begaud B: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc. Drugs Ther. 19(6), 403–414 (2005).
  • Time course and epidemiology of statin myopathy.
  • Silva MA, Swanson AC, Gandhi PJ, Tataronis GR: Statin-related adverse events: a meta-analysis. Clin. Ther. 28(1), 26–35 (2006).
  • Wierzbicki AS: Editorial: Statins: myalgia and myositis. Brit. J. Cardiol. 9, 193–194 (2002).
  • Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 289(13), 1681–1690 (2003)
  • Epidemiology of statin myopathy.
  • Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH: Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 177(1), 183–188 (2004).
  • Levak-Frank S, Radner H, Walsh A et al.: Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J. Clin. Invest. 96(2), 976–986 (1995).
  • Sirvent P, Mercier J, Vassort G, Lacampagne A: Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem. Biophys. Res. Commun. 329(3), 1067–1075 (2005).
  • Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD: Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler. Thromb. Vasc. Biol. 25(12), 2560–2566 (2005).
  • Baker SK, Tarnopolsky MA: Statin-associated neuromyotoxicity. Drugs Today (Barc.) 41(4), 267–293 (2005).
  • Lo YL, Leoh TH, Loh LM, Tan CE: Statin therapy and small fibre neuropathy: a serial electrophysiological study. J. Neurol. Sci. 208(1–2), 105–108 (2003).
  • Chong PH, Boskovich A, Stevkovic N, Bartt RE: Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 24(9), 1194–1203 (2004).
  • Reviews the mechanism of statin neuropathy.
  • Brass LM, Alberts MJ, Sparks L: An assessment of statin safety by neurologists. Am. J. Cardiol. 97(8A), S86–S88 (2006).
  • Caslake MJ, Packard CJ: Phenotypes, genotypes and response to statin therapy. Curr. Opin. Lipidol. 15(4), 387–392 (2004).
  • Maitland-van der Zee AH, Boerwinkle E: Pharmacogenetics of response to statins: where do we stand? Curr. Atheroscler. Rep. 7(3), 204–208 (2005).
  • Kuivenhoven JA, Jukema JW, Zwinderman AH et al.: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338(2), 86–93 (1998).
  • Winkelmann BR, Hoffmann MM, Nauck M et al.: Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J. 3(5), 284–296 (2003).
  • Miettinen TA, Kesaniemi YA: Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am. J. Clin. Nutr. 49(4), 629–635 (1989).
  • Cohen JC, Pertsemlidis A, Fahmi S et al.: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl Acad. Sci. USA 103(6), 1810–1815 (2006).
  • Kastelein JJ, Fouchier SW, Defesche JC: What promise does PCSK9 hold? J. Am. Coll. Cardiol. 45(10), 1620–1621 (2005).
  • Reviews roprotein convertase subtilisin kexin type (PCSK)-9 in lipid as a potential drug target.
  • Dubuc G, Chamberland A, Wassef H et al.: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosisregulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24(8), 1454–1459 (2004).
  • Tall AR: Protease variants, LDL, and coronary heart disease. N. Engl. J. Med. 354(12), 1310–1312 (2006).
  • Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH: Sequence variations in PCSK-9, low LDL and protection against coronary heart disease. N. Engl. J.Med. 354(12), 1264 –1272 (2006).
  • Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81(4A), B66–B69 (1998).
  • Davidson MH, Stein EA, Dujovne CA et al.: The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am. J. Cardiol. 79(1), 38–42 (1997).
  • Sheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH: The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111(23), 3051–3057 (2005).
  • Desager JP, Horsmans Y: Clinical pharmacokinetics of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31(5), 348–371 (1996).
  • Igel M, Sudhop T, von Bergmann K: metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. J. Clin. Pharmacol. 57(5), 357–364 (2001).
  • Law M, Rudnicka AR: Statin safety: a systematic review. Am. J. Cardiol. 97(8A), S52–S60 (2006).
  • Reviews the safety of statins.
  • Psaty BM, Furberg CD, Ray WA, Weiss NS: Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 292(21), 2622–2631 (2004).
  • Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30(11), 1280–1287 (2002).
  • Role of glucuronidation in statin metabolism.
  • Sacks FM: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardiol. 90(2), 139–143 (2002).
  • Consensus group statement of optimal HDL-C levels in cardiovascular disease.
  • Wierzbicki AS: Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr. Med. Res. Opin. 21(2), 299–306 (2005).
  • Scott R, Best J, Forder P et al.: Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovasc. Diabetol. 4, 13–22 (2005).
  • Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
  • Wierzbicki AS: FIELDS of dreams, fields of tears: a perspective on fibrate trials. Int. J. Clin. Pract. 60(4), 442–449 (2006).
  • Reviews the Fenofibrate Intervention in Event Lowering Diabetes (FIELD) trial and its conflicting results (2006).
  • Wierzbicki AS, Mikhailidis DP, Wray R et al.: Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr. Med. Res. Opin. 19(3), 155–168 (2003).
  • Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95(1), 120–122 (2005).
  • Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. Curr. Med. Res. Opin. 20(8), 1253–1268 (2004).
  • Use of nicotinic acid/nicotinic acid in raising HDL-C.
  • Canner PL, Berge KG, Wenger NK et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8(6), 1245–1255 (1986).
  • Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23), 3512–3517 (2004).
  • Bays HE, Dujovne CA, McGovern ME et al.: Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol- Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. 91(6), 667–672 (2003).
  • Barter PJ, Kastelein JJ: Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J. Am. Coll. Cardiol. 47(3), 492–499 (2006).
  • Utility of raising HDL-C with inhibition of cholesteryl ester transfer protein.
  • Brousseau ME, Schaefer EJ, Wolfe ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350(15), 1505–1515 (2004) 71. Wierzbicki AS.: Lipid-altering agents: the future. Int. J. Clin. Pract. 58(11), 1063–1072 (2004).
  • Novel drugs in human trials for hyperlipidaemia.
  • Jamil H, Chu CH, Dickson JK Jr et al.: Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J. Lipid Res. 39(7), 1448–1454 (1998).
  • Wetterau JR, Gregg RE, Harrity TW et al.: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 282(5389), 751–754 (1998).
  • Shiomi M, Ito T: MTP inhibitor decreases plasma cholesterol levels in LDL receptordeficient WHHL rabbits by lowering the VLDL secretion. Eur. J. Pharmacol. 431(1), 127–131 (2001).
  • Jin FY, Kamanna VS, Kashyap ML: Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol. 19(4), 1051–1059 (1999).
  • Lalanne F, Lambert G, Amar MJ et al.: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J. Lipid Res. 46(6), 1312–1319 (2005).
  • Wierzbicki AS, Lumb PJ, Cheung J, Crook MA: Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM 90(10), 631–634 (1997).
  • Taghibiglou C, Van Iderstine SC, Kulinski A, Rudy D, Adeli K: Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. Biochem. Pharmacol. 63(3), 349–360 (2002).
  • Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A: Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2. Curr. Opin. Lipidol. 12(3), 289–296 (2001).
  • Burnett JR, Wilcox LJ, Telford DE et al.: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J. Lipid Res. 40(7), 1317–1327 (1999).
  • Delsing DJ, Offerman EH, van Duyvenvoorde W et al.: Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterollowering effect in ApoE3-Leiden mice. Circulation 103(13), 1778–1786 (2001).
  • Bocan TM, Mueller SB, Brown EQ et al.: HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. Atherosclerosis 139(1), 21–30 (1998).
  • Insull W Jr, Koren M, Davignon J et al.: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 157(1), 137–144 (2001).
  • Sahi J, Milad MA, Zheng X et al.: Avasimibe induces CYP3A4 and MDR1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. 306, 1027–1034 (2003).
  • Wierzbicki AS: Atorvastatin. Expert Opin Pharmacother. 2(5), 819–830 (2001).
  • Nissen SE, Tuzcu EM, Brewer HB et al.: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354(12), 1253–1263 (2006).
  • Gylling H, Miettinen TA: Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism 48(5), 575–580 (1999).
  • Wasan KM, Zamfir C, Pritchard PH, Pederson RA: Influence of Phytostanol Phosphoryl Ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. J. Pharm. Sci. 92(2), 281–288 (2003).
  • Leitersdorf E: Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Int. J. Clin. Pract. 56(2), 16–19 (2002).
  • Altmann SW, Davis HR Jr et al.: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303(5661), 1201–1204 (2004).
  • Smart EJ, De Rose RA, Farber SA: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl Acad. Sci. USA 101(10), 3450–3455 (2004).
  • Ballantyne CM, Houri J, Notarbartolo A et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19), 2409–2415 (2003).
  • Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA: Efficacy of ezetimibe in patients with statin-resistant and statinintolerant familial hyperlipidaemias. Curr. Med. Res. Opin. 21(3), 333–338 (2005).
  • Gagne C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2469–2475 (2002).
  • Bays HE, Moore PB, Drehobl MA et al.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. 23(8), 1209–1230 (2001).
  • Mauro VF, Tuckerman CE: Ezetimibe for management of hypercholesterolemia. Ann. Pharmacother. 37(6), 839–848 (2003).
  • Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93(12), 1487–1494 (2004).
  • Simard C, Poirier P: Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor. Can. J. Cardiol. 22(2), 141–144 (2006).
  • Doherty E, Lumb PJ, Chik G, Wierzbicki AS: Ezetimibe-induced hyperlipidaemia. Int. J. Clin. Pract. (Suppl.) 147, S3–S5 (2005).
  • Jakulj L, Trip MD, Sudhop T, von BK, Kastelein JJ, Vissers MN: Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J. Lipid Res. 46(12), 2692–2698 (2005).
  • Farnier M, Freeman MW, Macdonell G et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26(9), 897–905 (2005).
  • Buchwald H, Varco RL, Matts JP et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N. Engl. J. Med. 323(14), 946–955 (1990).
  • The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 51–64 (1984).
  • Higaki J, Hara S, Takasu N et al.: Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 18(8), 1304–1311 (1998).
  • Krisans SK: The role of peroxisomes in cholesterol Metabolism. Am. J. Respir. Cell Mol. Biol. 7(4), 358–364 (1992).
  • Hogenboom S, Romeijn GJ, Houten SM, Baes M, Wanders RJ, Waterham HR: Absence of functional peroxisomes does not lead to deficiency of enzymes involved in cholesterol biosynthesis. J. Lipid Res. 43(1), 90–98 (2002).
  • Bae SH, Lee JN, Fitzky BU, Seong J, Paik YK: Cholesterol biosynthesis from lanosterol. Molecular cloning, tissue distribution, expression, chromosomal localization, and regulation of rat 7-dehydrocholesterol reductase, a Smith–Lemli–Opitz syndrome-related protein. J. Biol. Chem. 274(21), 14624–14631 (1999).
  • Jira PE, Wevers RA, de Jong J et al.: Simvastatin. A new therapeutic approach for Smith–Lemli–Opitz syndrome. J. Lipid Res. 41(8), 1339–1346 (2000).
  • Farmer JA: Pleiotropic effects of statins. Curr. Atheroscler. Rep. 2(3), 208–217 (2000).
  • Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A: Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr. Metab. Cardiovasc. Dis. 11(5), 328–343 (2001).
  • Kovacs WJ, Olivier LM, Krisans SK: Central role of peroxisomes in isoprenoid biosynthesis. Prog. Lipid Res. 41(5), 369–391 (2002).
  • Role of peroxisomes in cholesterol and isoprenoid synthesis.
  • Zhang D, Jennings SM, Robinson GW, Poulter CD: Yeast squalene synthase: expression, purification, and characterization of soluble recombinant enzyme. Arch. Biochem. 304(1), 133–143 (1993).
  • Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241–269 (1996).
  • Protein modification by isoprenoids as a mechanism of cellular control.
  • Ness GC, Zhao Z, Keller RK: Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 αhydroxylase. Arch. Biocem Biophys. 311(2), 277–285 (1994).
  • Hiyoshi H, Yanagimachi M, Ito M et al.: Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur. J. Pharmacol. 431(3), 45–52 (2001).
  • Sharma A, Slugg PH, Hammett JL, Jusko WJ: Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J. Clin. Pharmacol. 38(12), 1116–1121 (1998).
  • Bergstrom JD, Kurtz MM, Rew DJ et al.: Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl Acad. Sci. USA 90(1), 80–84 (1993).
  • Amin D, Rutledge RZ, Needle SN et al.: RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterollowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther. 281(2), 746–752 (1997).
  • Ugawa T, Kakuta H, Moritani H et al.: YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol. 131(1), 63–70 (2000).
  • Nishimoto T, Amano Y, Tozawa R et al.: Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br. J. Pharmacol. 139(5), 911–918 (2003).
  • Amano Y, Nishimoto T, Tozawa R, Ishikawa E, Imura Y, Sugiyama Y: Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur. J. Pharmacol. 466(1–2), 155–161 (2003).
  • Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y: Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem. Pharmacol. 66(11), 2133–2139 (2003).
  • Leung RK, Whittaker PA: RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107(2), 222–239 (2005).
  • Soutschek J, Akinc A, Bramlage B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173–178 (2004).
  • Zimmermann TS, Lee AC, Akinc A et al.: RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111–114 (2006).
  • Effects of interfering RNA therapy to apolipoprotein B in a monkey model.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.